reports
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results fo...
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that an abstract on its lead candidate, urcosimod (formerly OK-101), has been accepted for presentation at the prestigious 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. ...
OKYO Pharma Announces Successful Type C Meeting with the FDA
OKYO Pharma Announces Successful Type C Meeting with the FDA FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that it held a successful Type C meeting with the Food & Drug Administration (FDA) regarding the Phase 2b/3 human clinical trial of urcosimod for the treatm...
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment ...
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has authorized a single-patient expanded access (compassionate use) Investigational New Drug (IND) application submitted by Pedram Hamrah, MD, at the University of South Florida,...
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Execu...
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye dis...
OKYO Pharma to Ring the Opening Bell at Nasdaq
OKYO Pharma to Ring the Opening Bell at Nasdaq LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Executive Chairman and Founder, Gabriele Cerrone and the OKYO management team will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York today. The ceremony will be held from 9:15 AM to 9:45 AM E...
OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma Announces Chairman and Founder Acquires Shares LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company’s ordinary shares ...
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcome...
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that urcosimod may have a positive impact on corneal nerve health in patients with neuropathic corneal painCorneal nerve imaging data from the Phase 2 NCP trial were analyzed using in vivo confocal microscopy LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (N...
OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma Announces Chairman and Founder Acquires Shares LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 27,051 of the Company’s ordinary shares on NASDAQ, bringing his to...
OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma Announces Chairman and Founder Acquires Shares LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company’s ordinary shares on NASDAQ, bringing his to...
OKYO Pharma to Present at OIS XV in San Diego
OKYO Pharma to Present at OIS XV in San Diego LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Gary S. Jacob, Ph.D., Chief Executive Officer, will present at the Ophthalmology Innovation Summit (OIS) XV. The presentation is scheduled for Saturday, November 22, 2025, from 8:30-9:30 AM PT, as part of th...
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
OKYO Pharma to Present at BIO-Europe 2025 in Vienna LONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria. BIO-Europe, one of the largest and most impactful international life science ...
OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma Announces Chairman and Founder Acquires Shares LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 210,000 of the Company’s ordinary shares ...
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerat...
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announced it has received $1.9 million in non-dilutive funding to support its ongoing research and development programs. The funding wil...
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimo...
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment.Urcosimod (0.05%) demonstrated a marked reduction in pain scores as early as Week 4, with sustained efficacy maintained throughout the trial.A statistically significant reduction in mean pain scores was observed from Visit 1 to the end of treatment Visi...
OKYO Pharma to Present at the Bio International Convention
OKYO Pharma to Present at the Bio International Convention LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation during the Bio International Convention in Boston, MA. Dr. Jacob’s presentation will cover the development of urcosimod, OKYO’s lead clinical drug cand...
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob’s presentation will cover the development of...
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropa...
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP). Fast Track designation by the ...
OKYO Pharma Announces Plans to Accelerate the Clinical Development of ...
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans to analyze the efficacy data from the 17 patients who have now completed the Phase 2 trial.OKYO Pharma plans for a meeting with FDA following evaluation of clinical data. LONDON and NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology...
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimo...
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term StabilityUrcosimod stable in single-use ampoules for more than 2½ yearsFDA requires drug to show long-term shelf stability for approvalDaily administration to patients via ampoules can minimize risk of contamination LONDON and NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a...
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to...
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease, a multi-billion-dollar market, is pleased to announce the filing of its application for Fast Track designation with the U.S. Food and Drug Administration (FDA) for urcosimod (formerly kn...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.